APLT Company Profile and Key Details

Q: Who are the executives of APLT?

Mr. Chids MahadevanSenior Vice President of Fin. & Interim Principal Financial OfficerMr. Steven OrtegaChief Accounting Officer & Interim Principal Financial OfficerDr. Shoshana Shendelman Ph.D.Chair of the Board of Directors, Founder, Pres, Chief Executive Officer & Sec.Dr. Riccardo Perfetti M.D., Ph.D.Chief Medical OfficerMr. Adam HansardChief Commercial OfficerMs. Catherine ThorpeInterim Principal Financial Officer & Chief Accounting Officer

NASDAQ : APLT

Applied Therapeutics

$0.10

At Close 4:00 PM

Not Actively Trading

60.74

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Applied Therapeutics, Inc. (APLT) stock remained unchanged at $0.10 a share on NASDAQ. The stock opened at $0.10, fluctuating between $0.10 to $0.10 during the session.

Stock Snapshot

0.103

Prev. Close

14.86M

Market Cap

0.103

Day Low

-1.03

P/E Ratio

-0.1

EPS (TTM)

-0.65

Cash Flow per Share

0.1

Open

144.3M

Number of Shares

0.103

Day High

83.48%

Free Float in %

-0.2

Book Value

2.69M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 02, 2026	0.10	0.11	0.10	0.10	2.7M
Jan 30, 2026	0.09	0.10	0.09	0.10	1.56M
Jan 29, 2026	0.09	0.10	0.09	0.10	7.92M
Jan 28, 2026	0.09	0.10	0.09	0.09	10.63M
Jan 27, 2026	0.10	0.11	0.09	0.09	23.32M
Jan 26, 2026	0.10	0.10	0.10	0.10	9.49M
Jan 23, 2026	0.10	0.11	0.10	0.10	4.48M
Jan 22, 2026	0.10	0.11	0.10	0.11	7.61M
Jan 21, 2026	0.10	0.11	0.10	0.10	5.21M
Jan 20, 2026	0.10	0.11	0.10	0.10	8.55M
Jan 16, 2026	0.10	0.10	0.10	0.10	8.85M
Jan 15, 2026	0.10	0.10	0.10	0.10	70.92M
Jan 14, 2026	0.10	0.10	0.10	0.10	3.93M
Jan 13, 2026	0.10	0.10	0.10	0.10	3.3M
Jan 12, 2026	0.10	0.10	0.09	0.10	12.6M
Jan 09, 2026	0.10	0.10	0.10	0.10	5.18M
Jan 08, 2026	0.11	0.11	0.10	0.10	5.55M
Jan 07, 2026	0.11	0.11	0.10	0.11	7.12M
Jan 06, 2026	0.10	0.11	0.10	0.11	3.83M
Jan 05, 2026	0.10	0.11	0.10	0.10	7.4M

Contact Details

New York City, NY 10017

United States

https://www.appliedtherapeutics.com 212 220 9226

About Company

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

The stock is currently mid-range between its 52-week high and low $0.09 and $1.50. With a market capitalization of about $14.86 million, Applied Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.08). Key stats such as the average daily volume over the past year has been around 15.80 million shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Applied Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Les D. Funtleyder, the company employs approximately 35 people and listed since May 14, 2019. Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 2.41%, SMA50 -31.2%, SMA200 -77.78%). The stock’s 14-day RSI is 35.58 (weak momentum), while the ATR of 0.01 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -93.13% below its high and over 14.44% above its low.

Valuation Metrics

Applied Therapeutics, Inc. trades at a P/E ratio of -0.83, slightly below the S&P 500 average, with a price-to-sales ratio of 14.86 and a price-to-book ratio of -26.72 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.17, also below market averages.

Dividend & Fair Value

Applied Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.55. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Applied Therapeutics, Inc. generated EPS of -$0.10 over the past year. Five-year average earnings growth is 26.57%. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.20. Next year's EPS is expected at $45.30. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $2.00 to $2.00. The high target offers 1900.0% upside. The low target suggests 1900.0% downside. The mean target is $2.00. This offers 1900.0% upside. Applied Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -13.03%. The prior quarter beat by -11.76%. Over the last six quarters, Apple has recorded several small beats. These include 53.85% in November 07, 2024.

Shareholding & Insider Activity

Applied Therapeutics, Inc. has 144.30 million shares outstanding. The public float is 119.83 million shares, elevated short interest at 2.47% of float. This equals 3.54 million shares. The short ratio is 0.3 days. Institutional investors hold 71.52% of the float. Insiders own 5.39%. ALEXANDRIA REAL ESTATE EQUITIES, INC. holds 5.86 million shares, Shendelman Shoshana has 4.69 million shares and Alexandria Equities No. 7, LLC has 2.05 million shares. Over the past six months, insider transactions show net selling. They sold 43.00 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Applied Therapeutics generated $9.99M in revenue, or $0.12 per share. Gross margin was 96.47%, operating margin -645.80%, and net profit margin -1198.47%. Returns are negative, with ROA at -218.41% and ROE at 698.49%.
On valuation metrics, Applied Therapeutics trades at a P/E of -0.83, P/S of 14.86 and P/B of -26.72. Liquidity is tight, with a current ratio of 0.96 and quick ratio of 0.96. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 6018.86 days. Debt-to-equity is -4.46, supported by a cash flow-to-debt ratio of -34.74.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Applied Therapeutics posted revenue of $9.99M, down slightly from $0.00 in the prior quarter. Gross profit was $9.64M (margin 96.47%). Operating income was - $64.54M (margin -645.8%). Net income was- $119.76M (EPS - $1.42).
The company ended the quarter with $49.90M in cash and short-term investments, a total debt of $1.23M, and net debt of - $48.67M. Total assets were $54.83M, with equity of - $17.15M. Financials further reflected weakness, with operating cash flow of - $55.17M, free cash flow of - $55.17M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Applied Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -22.33%, with price expected at $0.08 by February 16, 2026, within a range of $0.06 to $0.11 3-Month Outlook: Projected rise of 385.44%, reaching $0.50 by May 01, 2026, with a range of $0.28 to $0.65. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 02, 2027, within a range of $0.00 to $0.21.

Key Takeaways

Applied Therapeutics, Inc. (NASDAQ:APLT) shares are flat 0.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Applied Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.83. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $17.98, suggesting 17356.31% upside. Our AI forecast model points to short-term weakness (-22.33% over two weeks), a medium-term rise (385.44% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Applied Therapeutics, Inc. (APLT) stock price?

Applied Therapeutics, Inc. (NASDAQ: APLT) stock price is $0.10 in the last trading session. During the trading session, APLT stock reached the peak price of $0.10 while $0.10 was the lowest point it dropped to. The percentage change in APLT stock occurred in the recent session was 0% while the dollar amount for the price change in APLT stock was $0.00.

APLT's industry and sector of operation?

The NASDAQ listed APLT is part of Biotechnology industry that operates in the broader Healthcare sector. Applied Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of APLT?

Mr. Chids Mahadevan
Senior Vice President of Fin. & Interim Principal Financial Officer
Mr. Steven Ortega
Chief Accounting Officer & Interim Principal Financial Officer
Dr. Shoshana Shendelman Ph.D.
Chair of the Board of Directors, Founder, Pres, Chief Executive Officer & Sec.
Dr. Riccardo Perfetti M.D., Ph.D.
Chief Medical Officer
Mr. Adam Hansard
Chief Commercial Officer
Ms. Catherine Thorpe
Interim Principal Financial Officer & Chief Accounting Officer

How APLT did perform over past 52-week?

APLT's closing price is 14.44% higher than its 52-week low of $0.09 where as its distance from 52-week high of $1.50 is -93.13%.

How many employees does APLT have?

Number of APLT employees currently stands at 35.

Link for APLT official website?

Official Website of APLT is: https://www.appliedtherapeutics.com

How do I contact APLT?

APLT could be contacted at phone 212 220 9226 and can also be accessed through its website. APLT operates from 545 Fifth Avenue, New York City, NY 10017, United States.

How many shares of APLT are traded daily?

APLT stock volume for the day was 2.69M shares. The average number of APLT shares traded daily for last 3 months was 15.8M.

What is the market cap of APLT currently?

The market value of APLT currently stands at $14.86M with its latest stock price at $0.10 and 144.3M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	35
Beta	2.08
Sales or Revenue	$9.99M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

APLT Company Profile and Key Details

Applied Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics